---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038596"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:14:23.533131+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics appoints Andrew Jackson as CFO effective Oct 30, 2023

## Summary
- Base salary $430k, annual bonus up to 35% of base, 300k incentive stock options with one-year cliff and 4-year vesting.
- Severance: 6 months' base salary if terminated without cause or resigns with good reason; 12 months after change of control.
- Jackson has over 25 years corporate finance experience, raised over $300M in financings, previously CFO at Eterna Therapeutics and Ra Medical Systems.
- Led Ra Medical's IPO and established public company processes, controls, and infrastructure.

## SEC filing metadata
- accession: 0001493152-23-038596
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315223038596/0001493152-23-038596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315223038596/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038596
- JSON: https://secwatch.observer/filing/0001493152-23-038596.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038596.txt

## Key facts
- Executive change
  Andrew Jackson was appointed as Chief Financial Officer at Calidi Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 27, 2023, the Board of Directors approved and ratified the appointment of Mr. Andrew Jackson as the Chief Financial Officer of the Company and the Compensation Committee approved and ratified the Employment Agreement with Mr. Andrew Jackson effective October 30, 2023 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315223038596/0001493152-23-038596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.